Join our membership
Find out about GHTC’s membership options and the benefits of becoming a member.Learn More
Sign up to receive news and updates from GHTC.
GHTC works to influence the US government and multilateral entities to commit resources and enact policies to spur the development of urgently needed vaccines, drugs, and other technologies for neglected and emerging global health challenges and ensure they are affordable and accessible to the communities who need them.
New tools and technologies are urgently needed to address global health challenges in under-resourced settings. Government investments in R&D are critical to jump-starting and advancing the development of technologies for neglected diseases and conditions with limited commercial markets.
Limited information-sharing, transparency, and coordination among players in global health R&D hinders efficient development and introduction of global health innovations. Increased coordination of global health R&D activities and actors can help fill critical gaps in the product development pipeline, foster strategic partnerships, and better leverage resources and learning.
The world’s most pressing global health challenges are too great to be solved by any one sector alone. Multisector partnerships that leverage the resources, skills, and expertise of governments, civil society, and the private sector are essential for advancing the research, development, rollout, and scale-up of global health technologies.
Regulatory review is a necessary step to ensure that new global health innovations intended for patients in need are safe and effective. Mechanisms that streamline and strengthen regulatory pathways and harmonize review requirements will help promote access to urgently needed global health technologies.
The private sector plays an important role in global health R&D. While it has tremendous resources to contribute to R&D for neglected diseases and conditions, limited prospects for financial return can often deter investment. Targeted and strategic incentives can encourage greater private-sector engagement in R&D for new global health technologies.